Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Tianhong Teng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2393-3001; OpenAlex author ID A5086916993, A5126779867. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2020: 3 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 12

  1. Futility of resection after neoadjuvant therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2026.115354↗
  2. Integrative Transcriptomic and Proteomic Profiling Defines Secretory and Immune Related Subtypes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.jproteome.5c01146↗
  3. Single-cell RNA-seq analysis reveals microenvironmental infiltration of myeloid cells and pancreatic prognostic markers in PDAC. Last author DOI 10.1007/s12672-025-01830-x↗
  4. An exploratory study of serum creatine kinase as a prognostic marker for patients with resectable pancreatic cancer: looking into the relationship with body co… Co-author DOI 10.1186/s12937-025-01084-x↗
  5. Metabolic, transcriptomic, and proteomic adaptations in pancreatic ductal adenocarcinoma-patient derived xenograft models across serial passages. Last author DOI 10.1186/s12967-025-06787-7↗
  6. Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the 'cold' microenvironment in pancreatic cancer. Last author DOI 10.1016/j.canlet.2024.217287↗
  7. Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction. Co-author DOI 10.1038/s41598-024-56737-4↗
  8. Mitochondria-Targeting Virus-Like Gold Nanoparticles Enhance Chemophototherapeutic Efficacy Against Pancreatic Cancer in a Xenograft Mouse Model. Co-author DOI 10.2147/ijn.s497346↗
  9. Metabolomic analyses redefine the biological classification of pancreatic cancer and correlate with clinical outcomes. First author DOI 10.1002/ijc.34208↗
  10. Photothermal augment stromal disrupting effects for enhanced Abraxane synergy chemotherapy in pancreatic cancer PDX mode. Co-author DOI 10.1039/d0bm00549e↗
  11. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma Co-author DOI 10.1097/jp9.0000000000000055↗
  12. Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolomic study. Co-author DOI 10.21037/gs-20-202↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heguang Huang · 6 shared papers, 2020–2025 · strength 1.22
  2. Ronggui Lin · 4 shared papers, 2020–2025 · strength 0.77
  3. Pengfei Guo · 4 shared papers, 2020–2025 · strength 0.74
  4. Jianghua Feng · 4 shared papers, 2020–2025 · strength 0.74
  5. Xianchao Lin · 4 shared papers, 2020–2025 · strength 0.72
  6. Jin Zhang · 2 shared papers, 2024 · strength 0.45
  7. Congfei Wang · 2 shared papers, 2020–2025 · strength 0.35
  8. Hao-Teng Luo · 1 shared paper, 2026 · strength 0.33
  9. Shizhao Lin · 1 shared paper, 2026 · strength 0.32
  10. Shangeng Weng · 1 shared paper, 2026 · strength 0.32
  11. Binbin Wei · 2 shared papers, 2020–2022 · strength 0.28
  12. Lili Wu · 1 shared paper, 2025 · strength 0.27
  13. Yanying Fan · 1 shared paper, 2025 · strength 0.27
  14. Fengchun Lu · 1 shared paper, 2025 · strength 0.25
  15. Cong Chen · 1 shared paper, 2025 · strength 0.25
  16. Wen Shi · 1 shared paper, 2025 · strength 0.23
  17. Heguang Huang · 2 shared papers, 2020 · strength 0.23
  18. Bing Chen Ma · 1 shared paper, 2024 · strength 0.19
  19. Yanbin Meng · 1 shared paper, 2024 · strength 0.19
  20. Qinglin Fei · 1 shared paper, 2020 · strength 0.13
  21. Yu Pan · 1 shared paper, 2020 · strength 0.13
  22. Maoen Pan · 1 shared paper, 2020 · strength 0.12
  23. Jieming Xie · 1 shared paper, 2020 · strength 0.11
  24. Minghuang Chen · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.